Compare BridgeBio Pharma Inc (BBIO) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Prudential PLC — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Prudential PLC trades at $27.46 (market cap $34.98B). The key difference: Prudential PLC is far larger — about 2.1× BridgeBio Pharma Inc's market cap, and Prudential PLC pays a 1.89% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PUK | |
|---|---|---|
Market Cap | $16.61B | $34.98B |
Sector | Health | Financials |
52-Week High | $90.17 | $33.61 |
52-Week Low | $47.29 | $24.98 |
Enterprise Value | $18.16B | $36.41B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Prudential Financial (PUK) trades at $28.28, up 1.43% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with Q2 2025 and Q4 2025 earnings beats, robust 14.52% net income margin, and improving cash flow trends. Recent news highlights China regulatory concerns impacting Asian-focused insurers, though Prudential reported solid Q2 2026 results with $985 million net income.
The stock presents value characteristics with a low P/E of 9.21, supported by analyst consensus leaning bullish (50% buy ratings). Key risks include China regulatory exposure and competitive pressures in Asian markets. Upside potential exists if the company successfully executes its capital-light strategy and navigates geopolitical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
